导师姓名： 吴斌 专业代码： 100700
性别： 男 专业名称： 药学
培养单位： 附属仁济医院 三级学科/
专业领域：
导师类型： 硕士生导师 专业学位导师：
联系方式：
邮编： 200127 邮箱地址： withtop@qq.com

研究方向 (点击浏览详细信息)
卫生与药物经济学/临床与卫生决策/卫生技术评估/循证医学与药学

社会任职
中国研究型医院药物经济学分会常委
Clinical drug investigation杂志编委（SCI索引期刊）
国际医疗卫生决策研究协会（SMDM）执委会委员
中国医疗保健国际交流促进会循证医学分会常委兼药物经济学学组组长
《中国现代应用药学》杂志青年编委（北大核心期刊）
《中国药房》杂志编委（北大核心期刊）

科研项目 项目编号项目名称课题来源起止年月批准经费承担职责
** 恶性肿瘤专属的效用积分体系构建与评估研究 国家自然科学基金管理学部海外合作项目 2018-01~2019-12 18万元 子课题负责人
15GWZK0901 “第四轮公共卫生三年行动计划重点学科建设计划----循证公共卫生与卫生经济学” 子课题：疾病管理视角下的肿瘤最优经济学防治路径研究 上海市卫生和计划生育委员会 2016-05~2017-12 90万元 课题负责人
** 基于离散事件仿真的2型糖尿病模型构建与相关防治策略的卫生经济学评价研究 国家自然科学基金管理学部面上项目 2014-01~2017-12 56万元 课题负责人

学术论文 作者论文标题期刊名出版年卷期页码
Zhu J, He W, Ye M, Fu J, Chu Y, Zhao Y, Zhang Y, Kuo D, Wu B （通讯作者） Cost–effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung Future Oncology 2018 doi: 10.2217/fon-2018-0321
Liu Y, Wang Z, Tobe R G, Lin H, Wu B （通讯作者） Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b Clinical drug investigation 2018 365-74
Wu B （通讯作者）, Wang Z, Zhang Q Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis Inflammatory bowel diseases 2018 10.1093/ibd/izy114
Zhou H, He J, Wu B （通讯作者）, Che D Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants Human Vaccines & Immunotherapeutics 2018 10.1080/**.2018.**
Wu B （通讯作者）, Tobe R G, Liu Y, He, B Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries Clinical drug investigation 2018 10.1007/s40261-018-0649-x
Wu B, Wan X, Ma J Cost-Effectiveness of Prevention and Management of Diabetic Foot Ulcer and Amputation in a Health Resource-limited Setting Journal of diabetes 2017 10.1111/1753-0407.12612
Lu S, Ye M, Ding L, Tan F, Fu J, Wu B （通讯作者） Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China Oncotarget 2017 8(6):9996-10006
Wu B （通讯作者）, Gu X, Zhang Q Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy Journal of thoracic oncology 2017 doi: 10.1016/j.jtho.2017.10.012.
Wu B, Yuan Y, Ke Z, Xuezhen M RAS testing and cetuximab treatment for metastatic colorectal cancer: A cost-effectiveness analysis in a setting with limited health resources Oncotarget 2017 2017. doi: 10.18632/oncotarget.17029
Yan X, Gu X, Xu Z, Lin H, Wu B （通讯作者） Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China Advances in Therapy 2017 2017,2(34):466-480
Wu B, Zhang S, Lin H, Mou S Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: a cost-effectiveness analysis J Diabetes Investig 2017 10.1111/jdi.12653
Wu B, Lin H, Tobe R G, Zhang L, He B Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials Journal of comparative effectiveness research 2017 10.2217/cer-2017-0074
Bai Y, Xu Y, Wu B （通讯作者） Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System Gastroenterology research and practice 2017 **
Wu B, Yang Z, Tobe R G, Wang Y Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis BJOG : an international journal of obstetrics and gynaecology 2017 10.1111/1471-0528.14786
Zhao D, Gai Tobe R, Cui M, He J, Wu B （通讯作者） Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China VACCINE 2016 34(50):6158-6165
Wu B, Li J, Lin H, Wu H Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation Journal of Ophthalmology 2016 12: 1-12
Lu S, Zhang J, Ye M, Wang B, Wu B （通讯作者） Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer Pharmacogenomics 2016 17(9):985-994
Yan X, Gu X, Zhou L, Lin H, Wu B （通讯作者） Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China Clinical drug investigation 2016 36(12):1001-1010
Zheng Y, Tang K, Ye L, Ai Z, Wu B （通讯作者） Mapping the neck disability index to SF-6D in patients with chronic neck pain Health and quality of life outcomes 2016 14: 21
Che D, Zhou H, Li T, Wu B （通讯作者） Duration and intensity of fluconazole for prophylaxis in preterm neonates: a meta-analysis of randomized controlled trials BMC Infectious Diseases 2016 16(1):1-7
Wu B, Song Y, Leng L, Bucala R, Lu LJ Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars Clinical and experimental rheumatology 2015 33: 20-26
Wu B, Li J, Wu H Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly Diagnosed Type 2 Diabetes: A Cost-Effectiveness Analysis Medicine (Baltimore) 2015 94: e1989
Li T, Liu M, Ben H, Xu Z, Zhong H, Wu B （通讯作者） Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting Clinical drug investigation 2015 35: 365-374
Wu B, Wu H, Liu X, Lin H, Li J Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials PLoS One 2014 9: e101253
Wu B, Kun L, Liu X, He B Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting Cardiovascular drugs and therapy 2014 28: 87-98
Wu B, Li T, Cai J, Xu Y, Zhao G Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy BMC Cancer 2014 14: 984
Che D, Zhou H, He J, Wu B （通讯作者） Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination BMC health services research 2014 14: 56
Zhu J, Li T, Wang X, Ye M, Cai J,Xu Y,Wu B （通讯作者） Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis BMC Cancer 2013 13: 39
Wei BJ, Chen YJ, Yu L, Wu B （通讯作者） Periodontal disease and risk of preeclampsia: a meta-analysis of observational studies PLoS One 2013 8: e70901
Wu B, Shen J, Cheng H Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China BMC health services research 2012 12: 385
Wu B, Miao Y, Bai Y, Ye M, Xu Y, et al Subgroup economic analysis for glioblastoma in a health resource-limited setting PLoS One 2012 7: e34588
Wu B, Dong B, Xu Y, Zhang Q, Shen J, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting PLoS One 2012 7: e32530
Bai Y, Ye M, Cao H, Ma X, Xu Y, Wu （通讯作者）, B Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting Breast cancer research and treatment 2012 136: 547-557
Wu B, Ye M, Chen H, Shen JF Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context Clinical therapeutics 2012 34: 468-479
Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, et al. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars PLoS One 2012 7: e47373
Wu B, Chen H, Shen J, Ye M Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China Clinical therapeutics 2011 33: 1446-1455
Wu B, Li T, Chen H, Shen J Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis Value in health 2010 13: 592-600